YK11 PharmaQO 60caps/5mg

YK11 PharmaQO 60caps/5mg for sale in the UK

YK-11 is a research-grade myostatin inhibitor and partial androgen receptor agonist supplied by Pharmaqo Labs in 60-capsule bottles dosed at 5 mg per capsule. Buy YK-11 UK from Power Anabolics for an experimental compound used by advanced researchers exploring myostatin pathway inhibition and follistatin upregulation — not a typical SARM and not a beginner option.

What is YK-11?

YK-11 is a synthetic compound derived from a 5α-dihydrotestosterone (DHT) scaffold with a 17α-methyl group, structurally closer to an anabolic steroid than to non-steroidal SARMs such as Ostarine or LGD-4033. Two mechanisms are reported in the literature: weak partial agonism at the androgen receptor and inhibition of myostatin (a negative regulator of muscle growth) via increased follistatin expression. Active half-life is short — roughly 6 to 10 hours based on the limited data available — which is why daily doses are typically split. Human clinical data is sparse; most evidence comes from in-vitro work and anecdotal user reports, and the 17α-methyl group is the same structural feature that drives liver stress in oral 17-aa anabolic steroids.

YK-11 benefits reported by users

• Reported lean mass gains via myostatin/follistatin pathway modulation
• Strength increases over short cycles
• Dry, hard appearance — no aromatisation, no water retention
• Stacks logically with non-suppressive endurance and recomposition compounds
• Convenient capsule format with consistent 5 mg dosing

Because robust human trials are missing, treat all "benefits" as anecdotal and weigh them against the suppression and hepatic risk profile below.

YK-11 dosage and cycle

Beginners: 5 mg/day. Intermediate: 5–10 mg/day split AM/PM. Advanced: up to 10 mg/day — higher doses are not supported by safety data. Cycle length is best kept short at 4–6 weeks due to safety unknowns and the 17α-methyl liver concern. Daily dosing is split into two administrations to match the short half-life. Female use is not advised — the partial AR agonism still carries virilisation risk and there is essentially no female-user safety record.

Side effects and PCT

Honest read-out of the risk profile: testosterone suppression is reported and PCT is required after every cycle. Hepatotoxicity is a real concern because of the 17α-methylated steroidal scaffold — liver markers can rise as they do with oral anabolic steroids, so a liver support product and pre/post bloods are sensible. No aromatisation and no water retention. Mild blood pressure elevation has been reported. Run a standard SERM-based PCT — PCT Tabs Pharmaqo covers Tamoxifen, Clomid and Proviron in one tablet and is the simplest option after a short YK-11 run. Stop immediately if jaundice, dark urine or right-upper-quadrant pain develop.

Stacks well with

YK-11 is most often paired with milder, better-studied compounds rather than other harsh agents. A common recomposition approach is Ostarine MK-2866 alongside YK-11 for lean tissue retention with manageable suppression, while endurance-focused users add Cardarine GW-501516 for fatty acid oxidation without further AR suppression. Stronger SARMs such as LGD-4033 or RAD-140 compound the suppression and hepatic burden — only experienced users should consider those combinations.

Frequently asked questions

How long does YK-11 take to start working?

Most users report perceptible strength and recovery changes within 1 to 2 weeks. Visible recomposition tends to follow over the rest of a 4 to 6 week cycle. Because YK-11's half-life is short, twice-daily dosing keeps blood levels steadier than a single morning dose.

Is YK-11 suitable for first-time users?

No. YK-11 is not a beginner compound. It carries hepatic risk from its 17α-methyl group, suppresses natural testosterone, and lacks the human safety data that supports milder options. First-time SARM users should start with Ostarine and only consider YK-11 after they understand cycle support and PCT.

Can YK-11 be detected on a drug test?

YK-11 is on the WADA prohibited list and modern sport anti-doping panels can detect it and its metabolites. Specific urinary detection windows are not well published due to limited assay studies, but assume any tested athlete is at risk for at least several weeks after the last dose.